The malignant hematology and stem cell transplant section, led by Dr. Marcos deLima includes hematologist-oncologists with special interest in hematologic malignancies. Clinical care is coordinated through a weekly multidisciplinary Tumor Board. The stem cell transplant program at University Hospitals, Case Medical Center has been in continuous operation since 1976 and is among the pioneering transplant programs in the United States. In 2012 we successfully passed our triennial certification through the Foundation for Accreditation in Cellular Therapy. We are active members in the Radiation Injury Transplant Network and NHLBI BMT Clinical Trials Network (CTN). We have a CLIA certified hematopoietic progenitor cellular facility and cellular therapy integrated services which coordinate collection and processing of all hematopoietic stem cell products.
We have implemented StemSoft, a BMT software program, which houses clinical and stem cell laboratory data, and allows for efficient communication with national registries. The hematologic tumor biorepository is a major priority, and serves as a resource to researchers. We have a large number of ongoing quality initiatives, such as a comprehensive discharge planning review, and maintain a robust programmatic quality management program which includes monthly review of complications and transplant outcomes (B. Cooper and B. McQuigg). Programmatic activities include maintenance of the standard operating procedures and the “Handbook for Blood and Marrow Transplantation” (B. Cooper). In addition, we have active participation in the Agency for Healthcare Research and Quality (AHRQ) initiative, Ohio on the CUSP. This initiative is focused on improving communication and reducing complications from central venous catheters. An interdisciplinary weekly “Transplant planning conference” was initiated in January 2013 which allows for a formal treatment and graft selection process in conjunction with the tissue typing laboratory team. Meanwhile, the transplant program continues to grow in breadth and scope. We are on track to perform at least 90 adult and pediatric allogeneic and autologous transplants in 2013. Future plans include an outpatient transplant program.